semaglutide camelback Flex-Dose 4 mL Injectable 2.5 mg/mL Home | Camelback Compounding Pharmacy

Long-term human safety has not been fully established

Lilly has announced promising data from its NCT 04881760 phase 2 study of retatrutide, a potential obesity drug

Eli Lilly says that Zepbound is a dual receptor agonist that targets both GIP and GLP-1 receptors, unlike other incretins approved for obesity management, which target only GLP-1 receptors. And Novo Nordisk says that Wegovy has the broadest GLP-1 label, including indications for reducing risk of major adverse cardiovascular events in some patients and for treatment of a certain liver condition in some adults

Treatment of cholinesterase poisoning from organophosphorus or carbamate insecticides